STOK Phase III Dravet therapy reports durable 75%+ seizure reduction
Long-term data for a Phase III Dravet syndrome therapy show sustained 75%+ seizure reduction and functional gains. The pivotal EMPEROR trial is fully enrolled, with endpoints spanning seizures and cognitive improvements.
A phase III Dravet syndrome therapy is approaching a key data readout, with long-term studies showing sustained 75%+ seizure reduction and functional gains. The pivotal EMPEROR trial is fully enrolled and is assessing both seizure reduction and cognitive improvements.